ProQR Therapeutics

Executive Summary

ProQR Therapeutics is a private biotechnology company based in Leiden, Netherlands, focused on developing RNA therapies for severe rare and common diseases using its proprietary Axiomer RNA-editing platform. Founded in 2021, the company aims to address unmet medical needs in genetic disorders by leveraging a technology that enables precise correction of RNA mutations without altering DNA. With offices in the Netherlands and Cambridge, Massachusetts, ProQR is advancing a pipeline of candidates targeting conditions such as Usher syndrome and other genetic eye diseases, with potential expansion into additional therapeutic areas. The platform's ability to edit RNA transiently offers a safety advantage over DNA editing approaches, positioning ProQR as a key player in the RNA therapeutics space. While the company remains in early stages, its technology has attracted interest from potential partners and investors. The upcoming catalysts include progress on its lead programs and platform validation through preclinical data. As a private entity, ProQR's success hinges on achieving clinical milestones to support future financing or partnership opportunities. The company's focus on rare diseases with high unmet need aligns with industry trends favoring precision genetic medicines.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for Lead Axiomer Program70% success
• H1 2027Series B Financing or Strategic Partnership60% success
• 2027IND Filing for First Clinical Candidate40% success